How Can We Help You with Your Projects?

Contact us to discuss the specifics of your project. Our team of experienced scientists is ready to assist you with tailored solutions to meet your unique needs. Whether you need help with assay development, FDA IND, stability study, lot release approval, or other scientific endeavors, we are here to support you.Contact us to learn more about our cell based assay services

How Long Does It Take to Get Started?

We will initiate your project as soon as the proposal is approved and signed by you. Our streamlined process ensures a quick start, minimizing delays and maximizing efficiency. Fill out the form below to email us or click our live chat option to speak with a MarinBio Scientist and get your project underway.

Can You Help with Assay Development and Validation for FDA IND, Lot Release and Stability Study Approval?

Yes, we have over 30 years of expertise in developing and validating cell based assays for FDA IND, lot release or stability study approval. Our team can also liaise directly with the FDA on your behalf, ensuring a smooth and compliant process. Please contact us to learn more about how we can assist you with your assay development and FDA approval needs.

Do You Need a Custom or Tailored Assay?

MarinBio scientists are experienced and creative in designing, developing, validating assays. Some of the assays we perform are listed below, but there are many more that we created, developed and validated. Give us call so that we may help you.

Innovations in Small-Molecule Cancer Therapeutics

Download the full article (PDF)

Structure-Guided Modulators and Degraders: The New Frontier in Precision Oncology Drug Development

Introduction

The landscape of targeted cancer therapy has expanded dramatically with the advent of sophisticated small-molecule modalities capable of modulating oncogenic proteins through mechanisms far beyond classical competitive inhibition. Historically, many of the most critical cancer drivers, including mutant RAS, lineage-defining transcription factors, and multi-domain scaffold proteins—were considered “undruggable” due to the absence of deep ligandable pockets or their reliance on protein-protein interactions rather than enzymatic active sites. Innovations in covalent chemistry, structural biology, degrader technologies, and E3 ligase engineering have transformed this paradigm. Modern agents can irreversibly trap mutant proteins in inactive conformations, rewire E3 ligase specificity to eliminate disease-driving substrates, or assemble multi-surface ternary complexes that induce degradation or disable signaling capacity. These modalities not only provide new avenues for precise engagement of cancer-specific dependencies but also offer more durable suppression of oncogenic pathways, reduced adaptive resistance, and enhanced potential for combination therapy. Collectively, these advances underscore a shift toward mechanism-rich therapeutics that dismantle the molecular architecture of malignant signaling networks more completely than traditional inhibitors, enabling deeper, more sustained clinical responses.

Inhibitors of RAS

RAS proteins are small GTPases that act as molecular switches controlling cell growth, survival, and metabolism; when mutated, they become locked in hyperactive signaling states that drive uncontrolled proliferation and are among the most common oncogenic drivers in human cancers. Covalent and tri-complex small-molecule RAS inhibitors represent complementary strategies for disabling these mutant signaling programs by exploiting structural features unique to oncogenic RAS. Covalent inhibitors are designed with special reactive groups that can latch onto a specific amino acid—cysteine—that becomes exposed only in certain mutant forms of RAS, such as KRAS-G12C. These inhibitors are shaped so they can slip into a temporary pocket on the protein, called the switch-II pocket, which appears only when RAS is in certain on/off states. By fitting into this pocket and locking onto the cysteine, the inhibitor traps RAS in its inactive, “off” form. This prevents RAS from switching on its usual signaling partners—like RAF kinases, PI3K, and RalGDS—thereby shutting down the pathways that drive cancer cell growth. Tri-complex inhibitors reach the same end goal as other RAS-blocking drugs but do it in a different way. Instead of forming a permanent bond with RAS, these molecules are built to latch onto the mutant RAS protein and a nearby hidden pocket or helper protein at the same time. By holding these pieces together, the inhibitor “locks” RAS into a shape where it can’t properly switch on. Because RAS stays stuck in this inactive state, the cell’s major growth-driving pathways (MAPK and PI3K–AKT) are dialed down. As a result, tumor cells make fewer growth-promoting genes, have a harder time taking up nutrients, and experience more metabolic and oxidative stress. Altogether, this pushes RAS-dependent cancer cells toward stopping their growth and becoming more vulnerable to programmed cell death. While covalent KRAS-G12C inhibitors are already clinically approved or in late-stage trials, and next-generation covalent inhibitors for additional mutants are advancing through early development, tri-complex RAS inhibitors remain in discovery and preclinical testing, with several programs nearing first-in-human studies.

Heterobifunctional (PROTAC) and Molecular-Glue Degraders

Heterobifunctional degraders (PROTACs) and molecular-glue degraders are complementary therapeutic strategies that harness the cell’s own ubiquitin-proteasome system to eliminate oncogenic proteins rather than merely inhibit them. PROTACs are heterobifunctional small molecules composed of a target-binding ligand linked to an E3 ligase recruiter, enabling enforced proximity between the target protein and the ubiquitination machinery; this drives polyubiquitin tagging and proteasomal destruction, producing durable pathway silencing, reduced feedback reactivation, and collapse of tumor-cell survival signaling, with several candidates now in early- to mid-phase clinical trials. In contrast, molecular glues are single-component degraders that bind an E3 ligase, and subtly reshape its interface to engage low-affinity or non-native substrates, allowing selective degradation of otherwise “undruggable” targets such as transcription factors and adaptor proteins. By removing these substrates, molecular glues disrupt transcriptional and signaling programs essential for malignant cell-cycle progression, proteostasis, and lineage-specific survival, reducing tumor viability; this class includes clinically validated agents and a growing pipeline of next-generation glues advancing through preclinical and early clinical development. Table 1. Examples of clinical-stage PROTACs

PROTAC name	Target molecule	Tumor killing mechanism	Therapeutic indication	Clinical stage
ARV-110	Androgen receptor (small-molecule AR ligand that binds AR LBD)	Degrading the androgen receptor removes the driver of AR-dependent transcription in prostate cancer (including some resistant AR variants), reducing AR signaling, promoting tumor cell differentiation/apoptosis and overcoming resistance to AR antagonists.	Metastatic castration- resistant prostate cancer	Phase 1/2
ARV-471	Estrogen receptor (small-molecule ER ligand that binds ER LBD)	ER degradation eliminates the receptor that drives proliferation in ER+ breast cancers (including some endocrine-resistant tumors), shutting down estrogen-driven transcription programs and causing growth arrest / cell death in ER-dependent tumor cells.	ER-positive (ER+)/HER2-negative advanced/ metastatic breast cancer.	Phase 1/2 through Phase 3 studies
NX-2127	Bruton’s tyrosine kinase (BTK) (BTK-binding warhead; cereblon-recruiting degrader)	BTK is essential for B-cell receptor signaling in many B-cell malignancies. Degrading BTK removes the signaling hub (including some BTK mutant forms resistant to inhibitors), blocking survival/proliferation signals and producing tumor cell apoptosis. NX-2127 additionally recruits cereblon and has immunomodulatory effects.	Relapsed / refractory B-cell malignancies (e.g., CLL, mantle cell lymphoma).	Phase 1a/1b
DT-2216	BCL-XL (BCL-xL inhibitor warhead; VHL-recruiting PROTAC)	BCL-XL is an anti-apoptotic protein that enables tumor cell survival by sequestering pro-apoptotic factors. Selective degradation of BCL-XL re-activates the intrinsic apoptotic pathway in BCL-XL-dependent tumors (with reduced platelet toxicity versus direct BCL-XL inhibitors).	Advanced solid tumors and hematologic malignancies	Phase 1

Allosteric Inhibitors of Signaling Proteins

Allosteric inhibitors are small molecules that bind to regulatory sites on a protein that are spatially distinct from the active site, inducing conformational or dynamic changes that reduce the protein’s activity rather than blocking substrate binding directly. This mechanism often provides greater selectivity, avoids competition with high-affinity endogenous ligands, and can disable mutant or drug-resistant conformations in cancer. Recent major advances have accelerated the development of such inhibitors, including: AI-guided mapping of cryptic allosteric pockets

Deep-learning and molecular-dynamics–integrated models identify transient, hidden pockets not seen in static structures and rank them by opening probability and druggability.
Focuses virtual screening on pockets that control long-range conformational switches, accelerating discovery of allosteric sites in hard-to-drug oncogenic proteins.

High-resolution cryo-EM structures revealing inaccessible regulatory surfaces

Visualizes full-length, flexible, or multi-domain oncogenic proteins in native-like states, exposing regulatory surfaces and allosteric pockets previously inaccessible to crystallography.
Provides ligand-bound vs. apo structural comparisons that reveal how small molecules stabilize inactive conformations, guiding rational allosteric inhibitor design.

Mutation-specific modeling of how oncogenic variants reshape allosteric networks

Atomistic simulations and ML-assisted energy landscape analyses show how cancer mutations rewire protein dynamics and allosteric communication pathways.
Identifies mutation-dependent regulatory vulnerabilities and enables selective design of inhibitors that preferentially stabilize inactive mutant conformations over wild-type.

These tools have driven the creation of next-generation KRAS allosteric agents (non-covalent, pan-mutant, and degrader-linked designs), EGFR mutant-selective allosteric inhibitors that overcome ATP-site resistance, and novel allosteric inhibitors of SHP2 and FGFR2 that are now entering or advancing through early clinical testing. Together, these advances show that allosteric targeting is becoming a mainstream strategy for drugging signaling nodes governing RAS/MAPK, RTK, and other oncogenic pathways previously considered intractable.

Mutation-Selective Kinase Inhibitors

Mutation-selective kinase inhibitors leverage subtle structural differences introduced by oncogenic mutations, such as gatekeeper mutations, activation loop rearrangements, or altered hydrophobic pockets, to achieve selective engagement of mutant kinases over their wild-type counterparts. These inhibitors often bind within mutant-specific pockets and block ATP binding or conformational transitions necessary for catalytic activity. This halts aberrant phosphorylation cascades that drive uncontrolled proliferation, survival signaling, and metastatic behaviors. By sparing wild-type kinases in normal tissues, these molecules can offer improved therapeutic windows and lower toxicity. Tumor cells reliant on the mutant kinase frequently undergo senescence, growth arrest, or apoptosis following pathway shutdown. Many mutation-selective inhibitors are already FDA-approved or in late-stage clinical trials, with next-generation agents targeting resistance mutations in advanced development. Table 2. Mutation-selective small-molecule kinase inhibitors

Inhibitor	Target protein	Class of mutation	Mechanism of inhibition	Clinical stage / regulatory status
Osimertinib (Tagrisso)	EGFR	T790M (and sensitizing EGFR mutations; also used first-line for Ex19del/L858R)	Third-generation, mutant-selective, irreversible EGFR TKI — covalently inhibits mutant EGFR while sparing much WT EGFR.	FDA approved for EGFR-mutant NSCLC (including T790M and broader EGFR-mutant indications).
Selpercatinib (Retevmo)	RET (receptor tyrosine kinase)	RET gene fusions and activating RET mutations (patient selection by RET fusion/mutation)	Potent, highly selective ATP-competitive RET kinase inhibitor that blocks RET autophosphorylation and downstream signaling in RET-driven tumors.	FDA approved for RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer.
Capmatinib (Tabrecta)	MET (receptor tyrosine kinase)	MET exon 14 skipping alterations	Potent, selective, ATP-competitive MET kinase inhibitor that inhibits MET auto phosphorylation and downstream signaling.	FDA approved for metastatic NSCLC with MET exon-14 skipping alterations.
Avapritinib (Ayvakit)	PDGFRA (and some KIT)	PDGFRA exon 18 activating mutations (notably D842V)	Potent inhibitor of activation-loop (exon-18) mutants — inhibits autophosphorylation of PDGFRA D842V and related resistant mutants.	FDA approved for unresectable/metastatic GIST with PDGFRA exon-18 mutations (including D842V).

Conclusion

The emergence of covalent inhibitors, tri-complex RAS modulators, heterobifunctional and next-generation degraders, molecular glues, E3-reprogramming compounds, mutation-selective inhibitors, and other multi-mechanistic small molecules represents a fundamental evolution in the strategy for drugging cancer. These chemotypes exploit unique conformational, mutational, or regulatory vulnerabilities within oncogenic proteins, enabling precise pathway suppression or targeted protein elimination that surpasses the capabilities of classical kinase inhibitors. By degrading essential transcription factors, locking RAS in inactive states, preventing cell-cycle progression, or reprogramming ubiquitination circuits, these agents disrupt the molecular infrastructure that tumors rely on for proliferation, survival, metabolic adaptation, and therapeutic resistance. Many of these technologies have advanced into clinical development, some already validated through regulatory approval, while others remain poised to expand the treatable landscape for cancers driven by historically inaccessible targets. As structural insights deepen and E3 ligase biology becomes increasingly mapped, next-generation small-molecule therapeutics will continue to refine the precision, potency, and durability of targeted cancer therapy. Together, these innovations promise a future in which previously undruggable oncogenic drivers become tractable therapeutic liabilities, enabling broader and more effective treatment options across cancer types. Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024. Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline. Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.